HCPCS Level II code J2792 represents an intravenous formulation of Rho(D) immune globulin, human, solvent detergent treated, in 100 IU units. This biologic product is used to provide passive immunization against Rho(D) antigen and is administered intravenously in outpatient infusion settings. Nationally, accurate coding for immune globulin therapies matters for clinical continuity, claims processing, and monitoring utilization of plasma-derived products.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines coverage and billing considerations across major national payers and presents clinical context for Rho(D) immune globulin use in prevention of Rho(D)-related alloimmunization.

Readers will find concise benchmarks and coding guidance relevant to billing and documentation: common sites of service for intravenous immune globulin, the service type, and payer landscape. The summary includes policy and coding updates where available, utilization considerations for infusion settings, and points for documentation to support medical necessity. Data not available in the input for payer-specific reimbursement rates, associated taxonomies, ICD-10 diagnoses, and related codes.